DLA PIPER LLP (US)

Lobbying for REGENXBIO INC. · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Maryland · House · Senate · $60,000.00 income · posted Apr 16, 2026

Lobbying activity 2

Health Issues

Issues related to rare disease.

Medical/Disease Research/Clinical Labs

Issues related to rare disease.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.